Form 8-K - Current report:
SEC Accession No. 0000950170-25-085479
Filing Date
2025-06-12
Accepted
2025-06-12 16:31:54
Documents
10
Period of Report
2025-06-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ntla-20250611.htm   iXBRL 8-K 143122
  Complete submission text file 0000950170-25-085479.txt   263997

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ntla-20250611.xsd EX-101.SCH 31890
12 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20250611_htm.xml XML 4930
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 251043299
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)